'ACE Eli Lilly Value Chain' Ranks No. 1 in Six-Month Returns Among Passive Healthcare ETFs
Six-Month Return of 11.79%
Korea Investment Management said on the 27th that the ACE Eli Lilly Value Chain ETF has posted the highest six-month return among passive healthcare-sector ETFs listed in Korea.
According to Koscom ETF Check, the ACE Eli Lilly Value Chain ETF posted a six-month return of 11.79% as of the previous day's closing price, the highest among passive healthcare products. There are currently 22 passive healthcare-sector products listed in Korea. The ETF's six-month return exceeded the average return of all products over the same period, which was -16.60%. Its one-year return stands at 17.85%.
The ACE Eli Lilly Value Chain ETF invests in around 15 companies expected to benefit across the entire production value chain, including raw material manufacturing, finished-product packaging and drug-delivery devices, with Eli Lilly, the pharmaceutical company with the world's largest market capitalization, at its center. As of the previous day, its top holdings included Eli Lilly (26.19%), Thermo Fisher Scientific (10.39%), Lonza Group (9.85%), United Therapeutics (7.67%) and Amphastar Pharmaceuticals (7.58%).
The ETF's performance reflects the success of its strategy of focusing on Eli Lilly, a leading company in GLP-1 treatments for obesity and diabetes that has established itself in the global pharmaceutical and biotechnology market, and its core partner ecosystem. Amid ongoing global supply shortages of Mounjaro, a diabetes treatment, and Zepbound, an obesity treatment, growth in earnings at Eli Lilly—driven by its own capacity expansions—as well as at suppliers of peptide active pharmaceutical ingredients (APIs) and contract development and manufacturing organization (CDMO) partners has driven the fund's performance.
Buoyed by revenue growth from injectable treatments, Eli Lilly raised its 2026 full-year revenue guidance from $82 billion-$85 billion to $85 billion-$87 billion. The company's global earnings outlook has also become clearer, supported by the successful launch in the U.S. market of Foundayo, a next-generation oral obesity treatment introduced in April 2026, and the European Medicines Agency's (EMA) recommendation for approval.
Nam Yong-soo, head of the ETF division at Korea Investment Management, said, "As demand in the global obesity treatment market grows, the supply-chain benefits from Eli Lilly's dominant market position and increased capital expenditure are translating into stronger earnings for value-chain companies. In addition, expanded access to prescriptions through U.S. Medicare, implemented in July 2026, is coinciding with a global rotation of capital into the healthcare sector and supporting share-price gains among related companies."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
He added, "The ACE Eli Lilly Value Chain ETF seeks long-term growth by investing in essential partners that are helping resolve production bottlenecks alongside Eli Lilly, which has delivered standout performance."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.